The role of sphingolipids in selected cardiovascular diseases;Rola sfingolipidów w wybranych chorobach układu kra̧żenia

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 67, Issue , 2013, Pages 1018-1026

  Kurek, Krzysztof ^a   Piotrowska, Dominika M ^b   Wiesiołek Kurek, Patrycja ^a   Chabowska, Anna ^c   Łukaszuk, Bartłomiej ^a   Zendzian Piotrowska, Małgorzata ^a  

^a Zak ad Fizjologii   (Poland)

^b Uniwersytetu Medycznego   (Poland)

^c Regionalne Centrum Krwiodawstwa i Krwiolecznictwa   (Poland)

Author keywords

Cardioprotection; Cardiovascular diseases; Ceramide; Sphingomyelin signaling pathway; Sphingosine 1 phosphate

Indexed keywords

CERAMIDE; CERAMIDE 1 PHOSPHATE; CERAMIDE 1-PHOSPHATE; DRUG DERIVATIVE; LYSOPHOSPHOLIPID; SPHINGOLIPID; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1-PHOSPHATE;

APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; HEART MUSCLE CELL; HUMAN; METABOLISM; PHYSIOLOGY; SECOND MESSENGER; SIGNAL TRANSDUCTION;

APOPTOSIS; CARDIOVASCULAR DISEASES; CERAMIDES; HUMANS; LYSOPHOSPHOLIPIDS; MYOCYTES, CARDIAC; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SPHINGOSINE;

EID: 84892565337     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1068694     Document Type: Article

References (57)

1. Aikawa M., Rabkin E., Okada Y., Voglic S. J., Clinton S. K., Brinckerhof C. E., Sukhova G. K., Libby P.: Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation, 1998;97:2433-2444
2. Argaud L., Prigent A. F., Chalabreysse L., Loufouat J., Lagarde M., Ovize M.: Ceramide in the antiapoptotic effect of ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol., 2004;286:H246-H251
3. Baranowski M., Błachnio A., Zabielski P., Górski J.: PPARα agonist induces the accumulation of ceramide in the heart of rats fed highfat diet. J. Physiol. Pharmacol., 2007;58:57-72
4. Baranowski M., Blachnio-Zabielska A., Hirnle T., Harasiuk D., Matlak K., Knapp M., Zabielski P., Gorski J.: Myocardium of type 2 diabetic and obese patients is characterized by alterations in sphingolipid metabolic enzymes but not by accumulation of ceramide. J. Lipid Res., 2010;51:74-80
5. Baranowski M., Górski J.: Heart sphingolipids in health and disease. Adv. Exp. Med. Biol., 2011;721:41-56
6. Baranowski M., Zabielski P., Blachnio A., Gorski J.: Effect of exercise duration on ceramide metabolism in the rat heart. Acta Physiol., 2008;192:519-529
7. Basu R., Oudit G. Y., Wang X., Zhang L., Ussher J. R., Lopaschuk G. D., Kassiri Z.: Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am. J. Physiol. Heart Circ. Physiol., 2009;297:H2096-H2108
8. Beresewicz A., Dobrzyń A., Górski J.: Accumulation of specific ceramides in ischemic/reperfused rat heart; effect of ischemic preconditioning. J. Physiol. Pharmacol., 2002;53:371-382
9. Bielawska A. E., Shapiro J. P., Jiang L., Melkonyan H. S., Piot C., Wolfe C. L., Tomei L. D., Hannun Y. A., Umansky S. R.: Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am. J. Pathol., 1997;151:1257-1263
10. Car H., Zendzian-Piotrowska M., Fiedorowicz A., Prokopiuk S., Sadowska A., Kurek K.: Rola ceramidów w wybranych patologiach mózgu: ischemia/hipoksja, choroba Alzheimera. Postȩpy Hig. Med. Dośw., 2012;66:295-303
11. Cavalli A. L., Ligutti J. A., Gellings N. M., Castro E., Page M. T., Klepper R. E., Palade P. T., McNutt W. T., Sabbadini R. A.: The role of TNFα and sphingolipid signaling in cardiac hypoxia: evidence that cardiomyocytes release TNFα and sphingosine. Basic Appl. Myol., 2002;12:167-175
12. Chiu H. C., Kovacs A., Ford D. A., Hsu F. F., Garcia R., Herrero P., Saffitz J. E., Schaffer J. E.: A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest., 2001;107:813-822
13. Cui J., Engelman R. M., Maulik N., Das D. K.: Role of ceramide in ischemic preconditioning. J. Am. Coll. Surg., 2004;198:770-777
14. Dawson E., George K., Shave R., Whyte G., Ball D.: Does the human heart fatigue subsequent to prolonged exercise? Sports Med., 2003;33:365-380
15. Dobrzyń A., Chocian G.: Sfingomielinowy szlak transmisji sygnałów. Medycyna Metaboliczna., 2003;7:75-80
16. Duan H. F., Wang H., Yi J., Liu H. J., Zhang Q. W., Li L. B., Zhang T., Lu Y., Wu C. T., Wang L. S.: Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Hum. Gene Ther., 2007;18:1119-1128
17. Finck B. N., Han X., Courtois M., Aimond F., Nerbonne J. M., Kovacs A., Gross R. W., Kelly D. P.: A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. USA, 2003;100:1226-1231
18. Gangoiti P., Camacho L., Arana L., Ouro A., Granado M. H., Brizuela L., Casas J., Fabriás G., Abad J. L., Delgado A., Gómez-Muñoz A.: Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease. Prog. Lipid Res., 2010;49:316-334
19. Gault C. R., Obeid L. M., Hannun Y. A.: An overview of sphingolipid metabolism: from synthesis to breakdown. Adv. Exp. Med. Biol., 2010;688:1-23
20. Glaros E. N., Kim W. S., Wu B. J., Suarna C., Quinn C. M., Rye K. A., Stocker R., Jessup W., Garner B.: Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem. Pharmacol., 2007;73:1340-1346
21. Hanada K.: Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim. Biophys. Acta, 2003;1632:16-30
22. Harmancey R., Wilson C. R., Taegtmeyer H.: Adaptation and maladaptation of the heart in obesity. Hypertension, 2008;52:181-187
23. Hernandez O. M., Discher D. J., Bishopric N. H., Webster K. A.: Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ. Res., 2000;86:198-204
24. Hofmann U., Burkard N., Vogt C., Thoma A., Frantz S., Ertl G., Ritter O., Bonz A.: Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion. Cardiovasc. Res., 2009:83:285-293
25. Hojjati M. R., Li Z., Zhou H., Tang S., Huan C., Ooi E., Lu S., Jiang X. C.: Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J. Biol. Chem., 2005;280:10284-10289
26. Holland W. L., Summers S. A.: Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev., 2008;29:381-402
27. Ichi I., Nakahara K., Miyashita Y., Hidaka A., Kutsukake S., Inoue K., Maruyama T., Miwa Y., Harada-Shiba M., Tsushima M., Kojo S.; Kisei Cohort Study Grooup: Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids, 2006;41:859-863
28. Jeong T., Schissel S. L., Tabas I., Pownall H. J., Tall A. R., Jiang X.: Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J. Clin. Invest., 1998;101:905-912
29. Jin Z. Q., Zhang J., Huang Y., Hoover H. E., Vessey D. A., Karliner J. S.: A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc. Res., 2007;76:41-50
30. Karapetyan A. V., Klyachkin Y. M., Selim S., Sunkara M., Ziada K. M., Cohen D. A., Zuba-Surma E. K., Ratajczak J., Smyth S. S., Ratajczak M. Z., Morris A. J., Abdel-Latif A.: Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction. Stem Cells Dev., 2013;22:1645-1656
31. Karliner J. S., Honbo N., Summers K., Gray M. O., Goetzl E. J.: The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J. Mol. Cell. Cardiol., 2001;33:1713-1717
32. Kim C., Schneider G., Abdel-Latif A., Mierzejewska K., Sunkara M., Borkowska S., Ratajczak J., Morris A. J., Kucia M., Ratajczak M. Z.: Ceramide-1-phosphate regulates migration of multipotent stromal cells and endothelial progenitor cells - implications for tissue regeneration. Stem Cells, 2013;31:500-510
33. Kitatani K., Idkowiak-Baldys J., Hannun Y. A.: The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell. Signal., 2008;20:1010-1018
34. Knapp M., Baranowski M., Czarnowski D., Lisowska A., Zabielski P., Górski J., Musiał W.: Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. Med. Sci. Monit., 2009;15:490-493
35. Knapp M., Zendzian-Piotrowska M., Błachnio-Zabielska A., Zabielski P., Kurek K., Górski J.: Myocardial infarction differentially alters sphingolipid levels in plasma, erythrocytes and platelets of the rat. Basic Res. Cardiol., 2012;107:294
36. Knapp M., Zendzian-Piotrowska M., Kurek K., Błachnio-Zabielska A.: Myocardial infarction changes sphingolipid metabolism in the uninfarcted ventricular wall of the rat. Lipids, 2012;47:847-853
37. Krown K. A., Page M. T., Nguyen C., Zechner D., Gutierrez V., Comstock K. L., Glembotski C. C., Quintana P. J., Sabbadini R. A.: Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J. Clin. Invest., 1996;98:2854-2865
38. Kurek K., Piotrowska D. M., Wiesiołek P., Chabowski A., Zendzian-Piotrowska M.: Role of sphingolipids in digestive system. Postȩpy Hig. Med. Dośw., 2012;66:868-875
39. Li Z., Basterr M. J., Hailemariam T. K., Hojjati M. R., Lu S., Liu J., Liu R., Zhou H., Jiang X. C.: The effect of dietary sphingolipids on plasma sphingomyelin metabolism and atherosclerosis. Biochim. Biophys. Acta, 2005;1735:130-134
40. Liu L., Shi X., Bharadwaj K. G., Ikeda S., Yamashita H., Yagyu H., Schaffer J. E., Yu Y. H., Goldberg I. J.: DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J. Biol. Chem., 2009;284:36312-36323
41. Mallat Z., Tedgui A.: Current perspective on the role of apoptosis in atherothrombotic disease. Circ. Res., 2001;88:998-1003
42. Means C. K., Brown J. H.: Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc. Res., 2009;82:193-200
43. Means C. K., Xiao C. Y., Li Z., Zhang T., Omens J. H., Ishii I., Chun J., Brown J. H.: Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2007;292:H2944-H2951
44. Park T. S., Rosebury W., Kindt E. K., Kowala M. C., Panek R. L.: Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice. Pharmacol. Res., 2008;58:45-51
45. Riboni L., Viani P., Bassi R., Prinetti A., Tettamanti G.: The role of sphingolipids in the process of signal transduction. Prog. Lipid Res., 1997;36:153-195
46. Sharma C., Smith T., Li S., Schroepfer G. J. Jr., Needleman D. H.: Inhibition of Ca2+ release channel (ryanodine receptor) activity by sphingolipid bases: mechanism of action. Chem. Phys. Lipids, 2000;104:1-11
47. Son N. H., Park T. S., Yamashita H., Yokoyama M., Huggins L. A., Okajima K., Homma S., Szabolcs M. J., Huang L. S., Goldberg I. J.: Cardiomyocyte expression of PPAR leads to cardiac dysfunction in mice. J. Clin. Invest., 2007;117:2791-2801
48. Takabe K., Paugh S. W., Milstien S., Spiegel S.: "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol. Rev., 2008;60:181-195
49. Tao R., Zhang J., Vessey D. A., Honbo N., Karliner J. S.: Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc. Res., 2007;74:56-63
50. Theilmeier G., Schmidt C., Herrmann J., Keul P., Schäfers M., Herrgott I., Mersmann J., Larmann J., Hermann S., Stypmann J., Schober O., Hildebrand R., Schulz R., Heusch G., Haude M. i wsp.: High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation, 2006;114:1403-1409
51. Vessey D. A., Kelley M., Li L., Huang Y., Zhou H. Z., Zhu B. Q., Karliner J. S.: Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med. Sci. Monit., 2006;12:BR318-BR324
52. Vessey D. A., Li L., Honbo N., Karliner J. S.: Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning. Am. J. Physiol. Heart Circ. Physiol., 2009;297:H1429-H1435
53. Vessey D. A., Li L., Kelley M., Karliner J. S.: Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. Biochem. Biophys. Res. Commun., 2008;375:425-429
54. Yang Q., Li Y.: Roles of PPARs on regulating myocardial energy and lipid homeostasis. J. Mol. Med., 2007;85:697-706
55. Zhang D. X., Fryer R. M., Hsu A. K., Zou A. P., Gross G. J., Campbell W. B., Li P. L.: Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res. Cardiol., 2001;96:267-274
56. Zhang J., Honbo N., Goetzl E. J., Chatterjee K., Karliner J. S., Gray M. O.: Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am. J. Physiol. Heart Circ. Physiol., 2007;293:H3150-H3158
57. Zhou Y. T., Grayburn P., Karim A., Shimabukuro M., Higa M., Baetens D., Orci L., Unger R. H.: Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. USA, 2000;97:1784-1789